Review Article

Laparoscopy-Assisted versus Open Hepatectomy for Live Liver Donor: Systematic Review and Meta-Analysis

Bin Zhang,^{1,2} Yu Pan,^{1,2} Ke Chen,^{1,2} Hendi Maher,² Ming-Yu Chen,^{1,2} He-Pan Zhu,^{1,2} Yi-Bin Zhu,^{1,2} Yi Dai,¹ Jiang Chen,¹ and Xiu-jun Cai¹

 ¹Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, 3 East Qingchun Road, Hangzhou, Zhejiang Province 310016, China
 ²School of Medicine, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang Province 310058, China

Correspondence should be addressed to Xiu-jun Cai; srrsh_cxj@zju.edu.cn

Received 22 June 2017; Revised 3 September 2017; Accepted 4 October 2017; Published 7 November 2017

Academic Editor: Kevork M. Peltekian

Copyright © 2017 Bin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To assess the feasibility, safety, and potential benefits of laparoscopy-assisted living donor hepatectomy (LADH) in comparison with open living donor hepatectomy (ODH) for liver transplantation. *Background.* LADH is becoming increasingly common for living donor liver transplant around the world. We aim to determine the efficacy of LADH and compare it with ODH. *Methods.* A systematic search on PubMed, Embase, Cochrane Library, and Web of Science was conducted in May 2017. *Results.* Nine studies were suitable for this analysis, involving 979 patients. LADH seemed to be associated with increased operation time (WMD = 24.85 min; 95% CI: -3.01 - 52.78, P = 0.08), less intraoperative blood loss (WMD = -59.92 ml; 95% CI: -94.58 - 25.27, P = 0.0007), similar hospital stays (WMD = -0.47 d; 95% CI: -1.78 - 0.83, P = 0.47), less postoperative complications (RR = 0.70, 95% CI: 0.51 - 0.94, P = 0.02), less analgesic use (SMD = -0.22; 95% CI: -0.44 - 0.11, P = 0.04), similar transfusion rates (RR = 0.82; 95% CI: 0.24 - 3.12, P = 0.82), and similar graft weights (WMD = 7.31 g; 95% CI: -23.45 - 38.07, P = 0.64). *Conclusion*. Our results indicate that LADH is a safe and effective technique and, when compared to ODH.

1. Introduction

Liver transplantation from living donors is a potential treatment for end-stage liver disease. And due, in part, to the limited number of available livers from deceased patients, living donor liver transplantation (LDLT) has become an established solution. Since the first successful LDLT for a child in 1989 [1], this life-saving procedure has developed rapidly, providing similar or even better outcomes, especially in children, in comparison with cadaver liver grafts [2]. Living donors are typically healthy adults; therefore the donor's safety is paramount.

Over the past two decades, laparoscopic surgery has been widely applied to liver surgery. In 2002, Cherqui et al. [3] reported the first case of laparoscopic living donor left lobectomy and laparoscopic LDLT was increasingly used in some centers. However, owing to technical difficulties, this procedure developed relatively slowly. The first case of laparoscopic-assisted hybrid living donor hepatectomy (LADH) was reported by Koffron et al. [4] in 2006, in which hands were introduced into the abdomen while still maintaining the pneumoperitoneum. In this procedure, a laparoscopic technique is employed for mobilization of liver and hilar dissection; however, the parenchymal transection is performed as an open procedure. As a result, this hybrid procedure achieved the advantage of avoiding a large subcostal incision while retaining the safety and familiarity of an open dissection and resection. In addition, laparoscopic-assisted surgeries offered surgeons an opportunity to accumulate expertise before converting to complete laparoscopic living donor hepatectomies.

Several studies have compared the outcome of laparoscopic-assisted living donor hepatectomy (LADH) with widely used open living donor hepatectomy (ODH). However, no consensus has been reached on this topic; it is still not clear which method is of more benefit to the donor. In this setting, we comprehensively collected relevant data and conducted a systematic review with meta-analysis to assess the feasibility, safety, and potential benefits of laparoscopicassisted living donor hepatectomy.

2. Materials and Methods

2.1. Systematic Literature Search. This meta-analysis was finished by searching electronic databases of PubMed, Embase, Cochrane Library, and Web of Science and scanning reference lists of articles in *May 2017* by Two investigators (B. Zhang and Y. Pan) independently. Strategies included the terms "laparoscopy", "laparoscopic", "minimally invasive", "hybrid", "hand-assisted", "hepatectomy", "liver resection", "hepatic resection", "living donor", and "liver donor". All eligible studies in English were retrieved, and their bibliographies were checked for potential relevant publications.

2.2. Eligibility Criteria. Studies comparing laparoscopyassisted and open living liver donor hepatectomy are included for the systematic review and meta-analysis including prospective or retrospective case series. Studies were excluded if they met any of the following criteria: (1) case reports, letters, reviews, editorials, and studies lacking control groups; (2) studies that did not report the type of surgery or operation data; (3) if dual (or multiple) studies were reported by the same institution and/or authors, only the most recent publication or the highest quality of studies was included. However, articles from the same authors or centers but with different patient cohorts were included.

2.3. Data Extraction and Quality Assessment. Two investigators (M. Y. Chen and H. P. Zhu) independently assessed publications for inclusion and extracted data from eligible studies, including the baseline characteristics, such as first author, publication year, country of region, study type, sample size, and operation outcomes (operation time and intraoperative estimated blood loss) and postoperative outcomes (overall complications and length of hospital stay). The primary outcomes of the study include blood loss, complications, and analgesic use. The secondary outcomes are operation time, transfusion, length of stay, and graft weights. We made attempts to contact corresponding authors for missing data points. Only one author provided requested data for analysis [5].

The quality of the researches was evaluated by The Newcastle-Ottawa Quality Assessment Scale (NOS). The scale ranged from 0 to 9 stars: studies achieving more than or equal to 6 are deemed as good methodologically.

2.4. Statistical Analysis. All analyses were performed with Review Manager Version 5.3 (The Cochrane Collaboration, Oxford, United Kingdom). Risk ratio (RR) with a 95% confidence interval (CI) was used for the comparison analysis of dichotomous variables. The same continuous parameters were expressed as weighted mean difference (WMD) in the same unit or standard mean difference (SMD) for different unit with 95% CI. When data in individual studies was presented as median and a range, the means and standard deviations (SDs) were estimated by Hozo et al. [6]. The test of heterogeneity, which indicated between-study variance, was evaluated according to Cochran's test and Higgins-squared statistic [7]. Pooled effects were calculated using a random-effects model, unless heterogeneity was less than 50% or P < 0.05. Graphical funnel plots were generated to determine visual inspections for publication bias.

We conduct subgroup analyses in the studies focusing on right lobe hepatectomies (RH) and left lobe hepatectomies (LH).

3. Results

3.1. Study Eligibility. A flowchart of the search strategies, containing reasons for excluding studies, is shown in Figure 1. No randomized controlled trials were identified in the records. Nine studies were selected for the final meta-analysis. Five studies [8, 10, 12, 14, 15] compared laparoscopy-assisted and open donor right hepatectomy and one study [11] compared left hepatectomy. Two studies [5, 13] had data for both right hepatectomy and left hepatectomy comparisons. One study [9] evaluated the safety and feasibility of mixed laparoscopicassisted donor right and left hepatectomies by comparing them with open donor hepatectomies.

A total of 979 patients were included in the analysis with 309 undergoing LADH (31.5%) and 670 undergoing OH (53.2%). Characteristics of included studies are summarized in Table 1. Four papers were conducted in Japan [5, 10, 11, 13], two in the United States [8, 9], one in China [15], one in Korea [14], and one in India [12]. Seven of the studies graded morbidity according to the Clavien-Dindo Classification. Four studies reported conversion in 10 cases, including diaphragmatic rupture (1 case), right hepatic vein injury (1 case), and IVC injury (1 case). And the other conversions were not documented in their respective studies. Three studies reported quality of life for donor in the follow-up period [11, 12, 14].

The quality of the research included was generally moderate to satisfactory. NOS shows that one out of the nine studies observed had 6 stars, six had 7 stars, and two had 8 stars. Table 2 shows the evaluation of quality according to NOS.

3.2. Meta-Analysis Results

3.2.1. Primary Outcome

Blood Loss. Intraoperative blood loss during surgery was significantly less for laparoscopy-assisted procedures compared to open ones (WMD = -59.92 ml; 95% CI: $-94.58 \sim -25.27$, P = 0.0007) (Figure 2). In the subgroup analysis, LADH was a protective effect against blood loss compared with ODH in RH (WMD = -57.56 ml; 95% CI: $-94.26 \sim -20.87$, P = 0.002). For the LH group, the results also show that LADH incurred lower blood loss (WMD = -91.50 ml; 95% CI: $-198.68 \sim 15.67$, P = 0.08). Furthermore, the difference was not significant in the mixed group (WMD = 300 ml; 95% CI: $-300.93 \sim 900.93$, P = 0.33).

Complication. All of the included studies reported complication rate. A reduced postoperative complication rate was

Author	Region	Study design	Year	Study period	Lobe	Incision	Approach	Sample size	Age (year)	BMI	Sex (M/F)	Follow-up (month)	Parenchyma dissection	Graft weight (g)	Wound infection rate (%)	Incisional hernia rate (%)	Dindo- Clavien
Baker et al. [8]	USA	OCS (R)	2009	2006-2008	Ri	UMI	LA Onen	33	37.0 ± 10.3 39.1 ± 11.1	25.8 ± 4.1 25.9 ± 4.3	15/18 13/20	3		900 ± 215 914 + 160	3.0		Yes
Thenappan et al. [9]	USA	OCS (R)	2011	2005-2009	Le, Ri	IMU	LA Open	15 15	33.9 ± 9.0 35.7 ± 8.1		7/8 6/9	I			6.7 0	6.7 13.3	No
Choi et al. [10]	Japan	OCS (R)	2012	2008-2011	Ri	IT	LA Open	20 90	29.7 ± 10.1 36.8 ± 12.0	23.6 ± 2.8 23.6 ± 2.9	12/8 58/32	I	CUSA CUSA		10 5.5	0 1.1	No
Marubashi et al. [11]	Japan	OCS (P)	2013	2009-2012	Le	IMU	LA Open	31 79	35.8 ± 8.4 37.8 ± 10.1	21.3 ± 3.6 22.6 ± 3.1	13/18 54/25	13.9 ± 9.8					Yes
Makki et al. [12]	India	OCS (P)	2014	2011-2013	Ri	IMU	LA Open	26 24	27.5 ± 9.4 32.4 ± 8.5	24.2 ± 3.6 24.5 ± 4.4	13/13 18/6	14 (6–22)		755.5 ± 87.9 725.8 ± 134.4	11.5 4.2		Yes
Soyama et al. [13]	Japan	OCS (R)	2015	1997–2014	Le, Ri	IMI	LA Open	67 137	41 (26–65) 39 (19–67)	21.6 (16.9–29.0) 22.1 (16.4–34.7)	33/34 57/80	27 21–86			0 1.5	0 0	Yes
Suh et al. [14]	Korea	OCS (P)	2014	2010-2013	Ri	IT	LA Open	14 268	24.9 ± 8.7 34 ± 9.7	20.9 ± 2.9 23.2 ± 3.0	206/62 3 1/13 3	2.6 (6.4–55.4)			0	0 0	Yes
Shen et al. [15]	China	OCS (R)	2016	2011-2014	Ri	IMU	LA Open	28 20	40.4 ± 11.1 38.3 ± 11.4	23.1 ± 1.8 21.9 ± 1.9	15/13 13/7	I	CUSA CUSA	634.2 ± 124.2 572.9 ± 122.5	0 0	0 0	Yes
Kitajima et al. [5]	Japan	OCS (R)	2017	2011-2016	Le, Ri	IMU	LA Open	153 77	42 (20–67) 43 (21–64)	22.4 (16.5–28.7) 22.7 (16.8–29.8)	36/40 43/34	36.6 (1.4–66)		$668~(460{-}1100)^*$ $655~(505{-}1025)^*$	0 1.3	0 0	Yes
OCS, observat: CUSA, Cavitro	onal clin n Ultrasc	ical study; . mic Surgici	P, prospe al Aspira	ctively collectu tor; [*] right.	ed data;	R, retrosp	ectively coll	ected data	a; LA: laparos	scopy-assisted;	O: open	: Le, left lobe; Ri	, right lobe; U	MI, upper mediar	n incision; ¹	ſI, transverse i	incision;

TABLE 1: Summary of studies included in the meta-analysis of laparoscopy-assisted versus open living donor hepatectomy.

Author	Matchad factors	Sel	lectior	n (out o	of 4)	Comparability (out of 2)	Outc	omes (c	out of 3)	Total (out of 0)
Autior	Matched factors	1	2	3	4	Comparability (out of 2)	5	6	$\overline{\mathcal{O}}$	10tal (0ut 01 9)
Baker et al. [8]	abcdef	*	*	*	*	* *	*			7
Thenappan et al. [9]	abcdef	*	*	*	*	* *	*			7
Choi et al. [10]	abcdefghijkl	*	*	*	*	* *	*			7
Marubashi et al. [11]	_	*	*	*	*	* *	*	*		8
Makki et al. [12]	abcd	*	*	*	*	*	*			6
Soyama et al. [13]	abcd	*	*	*	*	* *	*			7
Suh et al. [14]	_	*	*	*	*	*	*	*	*	8
Shen et al. [15]	abcd	*	*	*	*	* *	*			7
Kitajima et al. [5]	_	*	*	*	*	* *	*			7

TABLE 2: Quality assessment based on the NOS for observational studies.

Factors matched between groups: a: age; b: gender; c: body mass index; d: hepatic artery anomalies; e: portal vein anomalies; f: biliary anomalies; g: ALT; h: AST; i: hemoglobin; j: prothrombin time prothrombin time; k: prothrombin rate; l: international normalized ratio.



FIGURE 1: Flow diagram of included studies.

Otor has a such surround		Lap			Open		147.1.1.4	Mean difference	¥7	Mean differ	rence	
Study or subgroup	Mean	SD	Total	Mean	SD	Total	weight	IV, fixed, 95% CI	iear	IV, fixed, 95	% CI	
RH												
Baker et al., 2009	417	217	33	550	305	33	7.4%	-133.00 [-260.71, -5.29]	2009			
Choi et al., 2012	870	653	20	531.7	322.6	90	1.4%	338.30 [44.46, 632.14]	2012	-		
Makki et al., 2014	336.5	89.4	26	395.8	125.7	24	32.4%	-59.30 [-120.21, 1.61]	2014			
Sub, 2014	298.3	118.8	14	333	215.2	268	26.5%	-34.70 [-102.05, 32.65]	2014			
Soyama et al.,-R 2015	477	130.2	25	828.5	479.2	25	3.2%	-351.50 [-546.15, -156.85]	2015			
Shen et al., 2016	383.5	180.4	28	416.5	163.6	20	12.5%	-33.00 [-131.01, 65.01]	2016			
Kitajima et al.,-R 2017	286	309	41	330	339	39	5.9%	-44.00 [-186.36, 98.36]	2017	-+-		
Subtotal (95% CI)			187			499	89.2%	-57.56 [-94.26, -20.87]		•		
Heterogeneity: $\chi^2 = 17$.79, df = 6	6 (P = 0)	.007); I^2	= 66%								
Test for overall effect: Z	Z = 3.07 (P = 0.00	2)									
LH												
Marubashi et al., 2013	353	396	31	456	347	79	4.7%	-103.00 [-262.02, 56.02]	2013			
Soyama et al.,-L 2015	1,087.5	952.7	41	1,130	860.3	39	0.8%	-42.50 [-439.92, 354.92]	2015			
Kitajima et al.,-L 2017	347	336	35	435	343	38	4.9%	-88.00 [-243.83, 67.83]	2017			
Subtotal (95% CI)			107			156	10.5%	-91.50 [-198.68, 15.67]		•		
Heterogeneity: $\chi^2 = 0.0$	08, df = 2	(P = 0.9)	6); $I^2 =$	0%								
Test for overall effect: Z	2 = 1.67 (P = 0.09)									
RH+LH												
Thenappan et al., 2011	1,033	1,096	15	733	457	15	0.3%	300.00 [-300.93, 900.93]	2011			
Subtotal (95% CI)			15			15	0.3%	300.00 [-300.93, 900.93]				
Heterogeneity: Not app	licable											
Test for overall effect: Z	2 = 0.98 (P = 0.33	5)									
Total (95% CI)			309			670	100.0%	-59.92 [-94.58, -25.27]		•		
Heterogeneity: $\chi^2 = 19$.60, df = 1	10 (P = 0)	$(0.03); I^2$	= 49%					· · · ·		1	_
Test for overall effect: Z	2 = 3.39 (P = 0.00	07)						-1000	-500 0	500 1	000
Test for subgroup differ	ences: χ^2	= 1.73,	df = 2 (1)	P = 0.42)	$, I^2 = 0$	%				Favours [LA]	Favours [open]	
											- 1 -	

FIGURE 2: Forest plot of subgroup analyses—intraoperative blood loss. Lap: laparoscopy-assisted living donor hepatectomy, Open: open donor hepatectomy, RH: right lobe hepatectomy, LH: left lobe hepatectomy, and RH + LH: mixed group.

observed in the LADH group (RR = 0.70, 95% CI: 0.51~ 0.94, P = 0.02) (Figure 3(a)). In the subgroup analysis, LADH was comparable to ODH in RH group (RR = 0.95, 95% CI: 0.63~1.43, P = 0.80) and mixed group (RR = 0.59, 95% CI: 0.29~1.19, P = 0.14). However, complications were significantly decreased in LADH for LH procedures (RR = 0.43, 95% CI: 0.23~0.79, P = 0.007). There are no differences between the two groups regarding the Clavien grades I to IV and V complications (Figures 3(b), 3(c), and 3(d)). Postoperative complications included in this study are summarized in Table 3.

Analgesic Use. There are five studies that gave relevant information on analgesic use after surgery and postoperative pain was evaluated by the number of days of analgesic use or the dosage of analgesic. We found that analgesic use was significantly less in the LADH group (SMD = -0.22; 95% CI: $-0.44 \sim -0.11$, P = 0.04) (Figure 4).

3.2.2. Secondary Outcomes

Operative Time. Nine of the included studies [5, 8–15] reported operation times and mean operation time tended to be longer in LADH compared to ODH (WMD = 24.85 min; 95% CI: -3.01~52.78, P = 0.08) (Figure 5). Two of the studies [5, 13] provided data for right lobe hepatectomy (RH) and left lobe hepatectomy (LH), respectively, and we then did a

subgroup analysis of RH, LH, and mixed group. The subgroup analysis shows that there was no significant difference in operation time in LADH and ODH groups in RH (WMD = 23.86 min; 95% CI: $-13.72 \sim 61.44$, P = 0.21), LH (WMD = 20.92 min; 95% CI: $-26.85 \sim 68.69$, P = 0.39), and mixed (WMD = 52 min; 95% CI: $-11.89 \sim 68.894$, P = 0.11) subgroup.

Transfusion. Five studies reported transfusion information, with similar outcomes in both LADH and ODH (RR = 0.82; 95% CI: $0.24 \sim 3.12$, P = 0.82) (Figure 6).

Length of Hospital Stay. Length of hospital stay was similar between LADH and ODH (WMD = -0.47 d; 95% CI: $-1.78 \sim 0.83$, P = 0.47) (Figure 7). For the subgroup analysis, there were no significant difference between LADH and ODH in the RH group (WMD = -0.84 d; 95% CI: $-2.58 \sim 0.91$, P = 0.35), LH (WMD = 1.00 d; 95% CI: $-1.64 \sim 3.64$, P = 0.46), or the mixed group (WMD = -0.40 d; 95% CI: $-2.52 \sim 1.72$, P = 0.71).

3.2.3. Graft Weight. A total of 4 studies reported graft weight, showing no difference between the two groups (WMD = 7.31 g; 95% CI: $-23.45 \sim 38.07$, P = 0.64) (Figure 8).

3.2.4. Publication Bias. A funnel plot for studies reporting RRs of postoperative overall complications was used to detect publication bias. The plots standing for the studies distributed

						Complicatio	n (%)	
Author	Group	и	Event	Specified complications	1	2	ŝ	4
Dolrow of al [0]	LA	33	7	Small bowel injury × 1, biloma × 1, wound infection × 1	15.2	6.1	0	0
DANCI CLAI, [0]	0	33	7	Biloma × 1, pleural effusion × 1, bowel obstruction × 1	15.2	6.1	0	0
Thenemon of al [0]	\mathbf{LA}	15	2	Wound infection $\times 1$, incisional hernia $\times 1$				
тпепарран сган [2]	0	15	3	Biliary leakage × 1, incisional hernia × 2				I
Choi et al [10]	LA	20	9	Wound complication × 2, diaphragmatic hernia × 1, pleural effusion × 2, biliary stricture × 1	I	I	I	I
	0	06	21	Wound complication \times 5, ventral hernia \times 1, pleural effusion \times 4, bile leak \times 8, bleeding \times 1, portal versus thrombosis \times 2	I	I	I	I
Marihachi at al [11]	LA	31	ю	1	3.2	0	6.5	0
ואומו מחמאווו כו מוי נוון	0	79	17	1	8.9	1.3	11.3	0
Malthi at al [13]	LA	26	4	1	11.5	0	3.8	0
MIANNI CLAI, [12]	0	24	IJ	1	3.8	7.7	7.7	0
	LA	67	7	Biliary leakage × 2, postoperative bleeding × 2, bleeding of duodenal ulcer × 1, PV thrombus × 1, ileus × 1	6.0	0	4.5	0
Soyama et al. [13]				Biliary leakage \times 10, pleural effusion \times 2, infectious complication \times				
	0	137	25	3, nerve paralysis × 2, postoperative bleeding × 1, acute pancreatitis × 1, skin necrosis × 1, gastric stasis × 4, PV thrombus × 1	9.5	1.5	6.6	0.7
	LA	14	0	0	0	0	0	0
Suh et al. [14]	0	268	22	Hyperbilirubinemia \times 1, pleural effusion \times 6, ileus \times 5, wound seroma \times 2, bleeding \times 3, wound infection \times 3, biliary stricture \times 2	5.2	2.2	0.7	0
Shen et al. [15]	LA	28	Ŋ	Pleural effusion \times 2, pulmonary infection \times 1, ileus \times 1, intra-abdominal hemorrhage \times 1	7.1	7.1	0	0
	0	20	1	Pulmonary infection $\times 1$	0	5	0	0
	LA	76	17	Wound dehiscence × 2, intra-abdominal fluid collection × 4; hyperbilirubinemia × 1, fever × 2, renal failure × 1, small bowel	10.5	7.9	3.9	0
Kitajima et al. [5]				Wound dehiscence $\times 5$, pleural effusion $\times 2$, ascites, $\times 1$, portal Wound dehiscence $\times 5$, pleural effusion $\times 2$, ascites, $\times 1$, portal				
	0	77	23	venous thrombosis × 3, bile leakage × 5, drug-induced hepatotoxicity × 5, intraabdominal fluid collection × 1	19.5	3.9	6.5	0

TABLE 3: Systematic review of postoperative complications.

LA: laparoscopy-assisted living donor hepatectomy; open: open living donor hepatectomy.

Study of stud	\rightarrow
RH Baker et al., 2009 7 33 7 33 8.5% 1.00 [0.39, 2.53] 2009 • Choi et al., 2012 6 20 21 90 9.3% 1.29 [0.60, 2.77] 2012 • Sub, 2014 0 14 19 268 2.5% 0.46 [0.03, 7.25] 2014 • Makki et al., 2014 4 26 5 24 6.3% 0.74 [0.22, 2.43] 2014 •	\rightarrow
Choi et al., 2012 6 20 21 90 9.3% 1.29 [0.60, 2.77] 2012 Sub, 2014 0 14 19 268 2.5% 0.46 [0.03, 7.25] 2014 Makki et al., 2014 4 26 5 24 6.3% 0.74 [0.22, 2.43] 2014	\rightarrow
Sub, 2014 0 14 19 268 2.5% 0.46 [0.03, 7.25] 2014 Makki et al., 2014 4 26 5 24 6.3% 0.74 [0.22, 2.43] 2014	\rightarrow
Makki et al., 2014 4 26 5 24 6.3% 0.74 [0.22, 2.43] 2014	\rightarrow
Sham at al. 2016 E. 29. 1. 20. 1.40/ 2.57 [0.45.29.27] 2016	\rightarrow
Sheh et al., 2010 5 28 1 20 1.4% 5.5/ [0.45, 28.2/] 2010	
Kitajima et al.,-R 2017 9 41 13 39 16.2% 0.66 [0.32, 1.36] 2017	
Subtotal (95% CI) 162 474 44.2% 0.95 [0.63, 1.43]	
Total events 31 66	
Heterogeneity: $\chi^2 = 3.59$, df = 5 ($P = 0.61$); $I^2 = 0\%$	
Test for overall effect: $Z = 0.25 (P = 0.80)$ LH	
Marubashi et al., 2013 3 26 17 26 20.6% 0.18 [0.06, 0.53] 2013	
Kitajima et al.,-L 2017 8 35 10 38 11.6% 0.87 [0.39, 1.95] 2017	
Subtotal (95% CI) 61 64 32.3% 0.43 [0.23, 0.79]	
Total events 11 27	
Heterogeneity: $\chi^2 = 5.45$, df = 1 ($P = 0.02$); $I^2 = 82\%$	
Test for overall effect: $Z = 2.72$ ($P = 0.007$)	
RH + LH	
Thenappan et al., 2011 2 15 3 15 3.6% 0.67 [0.13, 3.44] 2011	
Soyama et al., 2015 7 67 25 137 19.9% 0.57 [0.26, 1.26] 2015	
Subtotal (95% CI) 82 152 23.6% 0.59 [0.29, 1.19]	
Total events 9 28	
Heterogeneity: $\chi^2 = 0.03$, df = 1 (<i>P</i> = 0.87); $I^2 = 0\%$	
Test for overall effect: $Z = 1.47$ ($P = 0.14$)	
Total (95% CI) 305 690 100.0% 0.70 [0.51, 0.94]	
Total events 51 121	
Heterogeneity: $\chi^2 = 12.07$, df = 9 (<i>P</i> = 0.21); $I^2 = 25\%$	
Test for overall effect: $Z = 2.34 (P = 0.02)$ 0.1 0.2 0.5 1 2 5	10
Test for subgroup differences: $\chi^2 = 4.84$, df = 2 ($P = 0.09$), $I^2 = 58.7\%$ Favours [LA] Favours [DA]	

(a)

Study or subgroup	La Events	p Total	Ope Events	en Total	Weight	Risk ratio M-H, fixed, 95% CI	Year		Risk r M-H, fixed	atio . 95% CI	
RH										,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Baker et al., 2009	5	33	5	33	14.1%	1.00 [0.32, 3.13]	2009				
Sub, 2014	0	14	14	268	4.3%	0.62 [0.04, 9.88]	2014	-			
Makki et al., 2014	3	26	1	24	2.9%	2.77 [0.31, 24.85]	2014			•	-
Shen et al., 2016	2	28	0	20	1.6%	3.62 [0.18, 71.57]	2016				
Kitajima et al.,-R 2017	5	41	8	39	23.1%	0.59 [0.21, 1.66]	2017				
Subtotal (95% CI) Total events	15	142	28	384	46.0%	0.97 [0.50, 1.86]					
Heterogeneity: $\chi^2 = 2.60$, d	f = 4 (P =	= 0.63);	$I^2 = 0\%$								
Test for overall effect: $Z = 0$ <i>LH</i>	0.10 (<i>P</i> =	0.92)									
Marubashi et al., 2013	1	31	7	79	11.1%	0.36 [0.05, 2.84]	2013				
Kitajima et al.,-L 2017	3	35	7	38	18.9%	0.47 [0.13, 1.66]	2017				
Subtotal (95% CI)		66		117	30.0%	0.43 [0.14, 1.27]				•	
Total events	4		14								
Heterogeneity: $\chi^2 = 0.04$, d	f = 1 (P =	= 0.84);	$I^2 = 0\%$								
Test for overall effect: $Z = 1$.53 (P =	0.13)									
RH + LH											
Soyama et al., 2015	4	67	13	137	24.0%	0.63 [0.21, 1.86]	2015				
Subtotal (95% CI)		67		137	24.0%	0.63 [0.21, 1.86]					
Total events	4		13						-		
Heterogeneity: Not applicab Test for overall effect: $Z = 0$	ole 0.84 (P =	0.40)									
Total (95% CI)		275		638	100.0%	0.72 [0.44, 1.19]					
Total events Heterogeneity: $\chi^2 = 3.97$, d	23 f = 7 (P =	= 0.78);	$55 I^2 = 0\%$					— I			
Test for overall effect: $Z = 1$.28 (P =	0.20)						0.02	0.1 1	10	50
Test for subgroup difference	es: $\chi^2 = 1$.69, df	= 2 (P =	0.43), I	$^{2} = 0\%$			F	avours [LA]	Favours [ope	n]
0 1	11	,	`								

FIGURE 3: Continued.

Study or subgroup	Laj	р	Opei	n	Weight	Risk ratio	Year	Risk ratio
Study of Subgroup	Events	Total	Events	Total	weight	M-H, fixed, 95% CI	Icai	M-H, fixed, 95% CI
RH								
Baker et al., 2009	2	33	2	33	16.7%	1.00 [0.15, 6.68]	2009	
Sub, 2014	0	14	6	268	5.7%	1.38 [0.08, 23.35]	2014	
Makki et al., 2014 Shen et al. 2016	0	26	2	24	21.7%	0.19 [0.01, 3.67]	2014	
Kitajima et al -R 2017		28	1	20	9.7%	1.43 [0.14, 14.70]	2016	
Subtotal (95% CI)	-1	41 1/2	2	39	71.0%	1.90 [0.37, 9.81]	2017	
Total events	8	142	13	504	/ 1.0 /0	1.00 [0.45, 2.02]		
Heterogeneity: $\gamma^2 = 1.90$,	df = 4(P)	= 0.75)	$: I^2 = 0\%$					
Test for overall effect: $Z = LH$	0.12 (P =	= 0.90)	,					
Marubashi et al., 2013	0	31	1	79	7.2%	0.83 [0.03, 19.92]	2013	
Kitajima et al.,-L 2017	2	35	1	38	8.0%	2.17 [0.21, 22.91]	2017	
Subtotal (95% CI)		66		117	15.2%	1.54 [0.24, 9.73]		
Total events	2		2					
Heterogeneity: $\gamma^2 = 0.23$,	df = 1 (P)	= 0.63)	$I^2 = 0\%$					
Test for overall effect: $Z =$	0 46 (P -	0.65)	,					
PH + IH	0.40 (1 =	- 0.05)						
Sovama et al. 2015	0	67	2	137	13.8%	0 41 [0 02 8 34]	2015	
Subtotal (95% CI)	0	67	2	137	13.8%	0.11 [0.02, 0.31] 0.41 [0.02, 8.34]	2015	
Total events	0	07	2	157	15.070	0.11 [0.02, 0.04]		
Hatana gan aitar Nat annli a	hla		2					
Heterogeneity: Not applica	ible							
Test for overall effect: $Z = 1$ Total (95% CI)	0.58 (P =	0.56) <i>275</i>		638	100.0%	1.04 [0.48, 2.27]		
Total events	10		17					Ī
Heterogeneity: $\chi^2 = 2.68$,	df = 7 (P	= 0.91)	; $I^2 = 0\%$				r	·····
Test for overall effect: $Z =$	0.10 (P =	0.92)					0.0	0.1 0.1 1 10 100
Test for subgroup difference	e^{2} –	0.55 df	-2(P -	0.76)	$I^2 - 0\%$			Favours [LA] Favours [open]
Test for subgroup unierent		0.55, ui	- 2 (1 -	0.70), 1	- 070			
						(c)		
	La	p	Oper	n	TAT 1 1 .	Risk ratio	37	Risk ratio
Study or subgroup	Laj Events	p Total	Oper Events	n Total	Weight	Risk ratio M-H, fixed, 95% CI	Year	Risk ratio M-H, fixed, 95% CI
Study or subgroup	Laj Events	p Total	Oper Events	n Total	Weight	Risk ratio M-H, fixed, 95% CI	Year	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009	Laj Events 0	p Total 33	Oper Events 0	n Total 33	Weight	Risk ratio M-H, fixed, 95% CI Not estimable	Year	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014	Laj Events 0 0	p Total 33 26	Oper Events 0 2	n Total 33 24	Weight	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67]	Year 2009 2014	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014	Laj Events 0 0 0	p Total 33 26 14	Oper Events 0 2 2	n Total 33 24 268	Weight 13.0% 1.3%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43]	Year 2009 2014 2014	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016	Laj Events 0 0 0 1	p Total 33 26 14 28	Oper Events 0 2 2 0	n Total 33 24 268 20	Weight 13.0% 1.3% 2.9%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74]	Year 2009 2014 2014 2016	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al., -R 2017	Laj Events 0 0 0 1 0	p Total 33 26 14 28 41	Oper Events 0 2 2 0 3	n Total 33 24 268 20 39	Weight 13.0% 1.3% 2.9% 18.0%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55]	Year 2009 2014 2014 2016 2017	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al.,-R 2017 Subtotal (95% CI)	Laj Events 0 0 0 1 0	p Total 33 26 14 28 41 142	Oper Events 0 2 2 0 3	n Total 33 24 268 20 39 384	Weight 13.0% 1.3% 2.9% 18.0% 35.3%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60]	Year 2009 2014 2014 2016 2017	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al.,-R 2017 Subtotal (95% CI) Total events	Laj Events 0 0 1 0	p Total 33 26 14 28 41 142	Open Events $ \begin{array}{c} 0\\2\\0\\3\\\end{array} $	n Total 33 24 268 20 39 384	Weight 13.0% 1.3% 2.9% 18.0% 35.3%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60]	Year 2009 2014 2014 2016 2017	Risk ratio M-H, fixed, 95% CI
Study or subgroup \overline{RH} Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al.,-R 2017 Subtotal (95% CI) Total events Heterogeneity: $\chi^2 = 3.78$, of Total events	Lag Events 0 0 0 1 0 1 df = 3 (P)	$\begin{array}{c} p \\ Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ 0.22) \end{array}$	Open Events $ \begin{array}{c} 0\\2\\0\\3\\\\; I^2 = 219\end{array} $	n Total 33 24 268 20 39 384 %	Weight 13.0% 1.3% 2.9% 18.0% 35.3%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60]	Year 2009 2014 2014 2016 2017	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al., -R 2017 Subtotal (95% CI) Total events Heterogeneity: $\chi^2 = 3.78$, 6 Test for overall effect: $Z = LH$	Laj Events 0 0 1 0 1 1 0 4f = 3 (P 1.23 (P =	$\begin{array}{c} p \\ \hline Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \end{array}$	Open Events 0 2 0 3 $; I^2 = 219$	n Total 33 24 268 20 39 384 %	Weight 13.0% 1.3% 2.9% 18.0% 35.3%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60]	Year 2009 2014 2014 2016 2017	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013	Lap Events $0 \\ 0 \\ 0 \\ 1 \\ 0 \\ 0 \\ 1 \\ 0 \\ df = 3 (P = 2 \\ 2 \\ 2 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\$	p = Total $33 = 26$ $14 = 28$ $41 = 142$ $= 0.29$ $= 0.22$ $31 = -2$	Oper Events 0 2 2 0 3 $; I^2 = 219$ 9	n Total 33 24 268 20 39 384 %	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60]	Year 2009 2014 2014 2016 2017 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017	Lap Events $0 \\ 0 \\ 0 \\ 1 \\ 0 \\ df = 3 (P = 2 \\ 3 \\ 3 \\ df = 3 \\ (P = 2 \\ 3 \\ df = 3 \\ (P = 2 \\ 3 \\ df = 3 \\ (P = 2 \\ d$	p = Total 33 26 14 28 41 142 = 0.29) = 0.22) 31 35	Open Events 0 2 2 0 3 ; $I^2 = 215$ 9 2	Total 33 24 268 20 39 384 % 79 38	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18]	Year 2009 2014 2014 2016 2017 2013 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)	Lap Events $0 \\ 0 \\ 0 \\ 1 \\ 0 \\ df = 3 (P = 2 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\ 3 \\$	p = Total 33 26 14 28 41 142 = 0.29) = 0.22) 31 35 66	Open Events 0 2 2 0 3 7 ; $I^2 = 210$ 9 2	Total 33 24 268 20 39 384 % 79 38 117	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55]	Year 2009 2014 2014 2016 2017 2013 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total events	Lap Events $0 \\ 0 \\ 0 \\ 1 \\ 0 \\ df = 3 (P = 2 \\ 3 \\ 5 \\ 5$	$\begin{array}{c} P \\ Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \end{array}$	Open Events 0 2 2 0 3 7 ; $I^2 = 219$ 9 2 11	Total 33 24 268 20 39 384 % 79 38 117	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55]	Year 2009 2014 2014 2016 2017 2013 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, or	Lap Events 0 0 0 1 0 1 1 2 3 f = 3 (P = 2) 2 3 f = 1 (P)	$\begin{array}{c} P \\ Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \\ = 0.36) \end{array}$	Open Events 0 2 0 3 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$	Total 33 24 268 20 39 384 % 79 38 117	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55]	Year 2009 2014 2014 2016 2017 2013 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, qTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, qTest for overall effect: $Z = 1000$ Test for overall effect: $Z = 1000$ Test for overall effect: $Z = 1000$	Lap Events 0 0 0 1 0 1 1 2 3 f = 3 (P = 2) 2 3 f = 1 (P = 1) 0 0 0 1 0 1 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 1 0 1 1 2 3 (P = 2) 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	P = Total 33 26 14 28 41 142 = 0.29) = 0.22) 31 35 66 = 0.36) = 0.78)	Open Events 0 2 0 3 7 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$	Total 33 24 268 20 39 384 % 79 38 117	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55]	Year 2009 2014 2014 2016 2017 2013 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$	Lap Events 0 0 0 1 0 1 1 1 2 3 $f = 3 (P = 2^{-1})^{-1}$ $f = 1 (P = 0.28 (P = 1^{-1})^{-1})^{-1}$	$\begin{array}{c} P \\ Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \\ = 0.36) \\ = 0.78) \end{array}$	Open Events 0 2 0 3 7 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$	Total 33 24 268 20 39 384 % 79 38 117	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55]	Year 2009 2014 2014 2016 2017 2013 2013	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015	Lap Events 0 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	P = Total 33 26 14 28 41 142 = 0.29) = 0.22) 31 35 66 = 0.36) = 0.78) 67	Open Events 0 2 0 3 7 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$ 9	Total 33 24 268 20 39 384 % 79 38 117 137	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55]	Year 2009 2014 2014 2016 2017 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)	Lap Events 0 0 0 1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 2 3 df = 3 (P 1 2 3 df = 1 (P 2 3 df = 1 (P 3 df = 1 (P) 3 df = 1 (P) df = 1 (P)	$\begin{array}{c} P \\ \hline Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \\ = 0.36) \\ = 0.78) \\ 67 \\ 67 \\ 67 \end{array}$	Open Events 0 2 0 3 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$ 9	Total 33 24 268 20 39 384 % 79 38 117 137 137	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2014 2016 2017 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)Total events	Lap Events 0 0 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1	$\begin{array}{c} P \\ \hline Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \\ = 0.36) \\ = 0.78) \\ 67 \\ 67 \\ 67 \end{array}$	Open Events 0 2 0 3 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$ 9 9	Total 33 24 268 20 39 384 % 79 38 117 137 137	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2014 2016 2017 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)Total events	Lap Events 0 0 0 1 1 2 3 (P = 2 3 5 5 1 (P = 1 (P = 3 (P = 1 (P = 1) (P = 2 3) 5 1 (P = 3 (P = 3) 2 3 (P = 3) 5 1 (P = 3 (P = 3) 5 1 (P = 3 (P = 3) 5 (P = 3) 3) 5 (P = 3) 3) (P = 3) (P = 3) (P = 3) (P = 3) (P = 3) (P = 3) (P = 3) (P = (P = 3) (P = (P = ($\begin{array}{c} p\\ Total\\ 33\\ 26\\ 14\\ 28\\ 41\\ 142\\ = 0.29)\\ = 0.22)\\ 31\\ 35\\ 66\\ = 0.36)\\ = 0.78)\\ 67\\ 67\\ 67\end{array}$	Open Events 0 2 0 3 7 9 2 11 ; $I^2 = 0\%$ 9 9	Total 33 24 268 20 39 384 % 79 38 117 137 137	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)Total eventsHeterogeneity: Not applicaTest for overall effect: $Z = 7$	Lap Events 0 0 0 1 1 2 3 (P = 2 3 5 5 1 (P = 1 (P = 3 (P = (P =	$\begin{array}{c} p\\ Total\\ 33\\ 26\\ 14\\ 28\\ 41\\ 142\\ = 0.29)\\ = 0.22)\\ 31\\ 35\\ 66\\ = 0.36)\\ = 0.78)\\ 67\\ 67\\ 0.56)\end{array}$	Open Events 0 2 0 3 7 9 2 11 ; $I^2 = 0\%$ 9 9	Total 33 24 268 20 39 384 % 79 38 117 137 137	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)Total eventsHeterogeneity: Not applicationTest for overall effect: $Z = T$ Test for overall effect: $Z = T$	Lap Events 0 0 0 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0 1 0 1 1 0 1 1 2 3 2 3 df = 1 (P 1.23 (P = 2 3 df = 1 (P 0.28 (P = 3 df = 1 (P) 0.28 (P = 3 df = 1 (P) 0.59	$\begin{array}{r} p\\ Total\\ 33\\ 26\\ 14\\ 28\\ 41\\ 142\\ = 0.29)\\ = 0.22)\\ 31\\ 35\\ 66\\ = 0.36)\\ = 0.78)\\ 67\\ 67\\ 0.56)\\ 275\end{array}$	Oper Events 0 2 2 0 3 ; $I^2 = 219$ 9 2 11 ; $I^2 = 0\%$ 9 9 9 9	Total 33 24 268 20 39 384 % 79 38 117 137 137 137 638	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7% 29.7% 100.0%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)Total eventsHeterogeneity: Not applicationTest for overall effect: $Z = T$ Total (95% CI)Total eventsHeterogeneity: Not applicationTest for overall effect: $Z = T$ Total (95% CI)Total eventsTest geneity: Not applicationTest for overall effect: $Z = T$ Total (95% CI)Total eventsTest geneity: Not applicationTest for overall effect: $Z = T$ Total (95% CI)Total events	Lap Events 0 0 0 1 1 2 3 (P = 2 3 5 5 1 (P = 3 (P = (P =	$\begin{array}{c} p\\ Total\\ 33\\ 26\\ 14\\ 28\\ 41\\ 142\\ = 0.29)\\ = 0.22)\\ 31\\ 35\\ 66\\ = 0.36)\\ 67\\ 67\\ 0.56)\\ 275\end{array}$	Oper Events 0 2 2 0 3 $; I^2 = 219$ 9 2 11 $; I^2 = 0\%$ 9 9 2	Total 33 24 268 20 39 384 % 79 38 117 137 137 638	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7% 100.0%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al., -R 2017 Subtotal (95% CI) Total events Heterogeneity: $\chi^2 = 3.78$, of Test for overall effect: $Z = LH$ Marubashi et al., 2013 Kitajima et al., -L 2017 Subtotal (95% CI) Total events Heterogeneity: $\chi^2 = 0.83$, of Test for overall effect: $Z = RH + LH$ Soyama et al., 2015 Subtotal (95% CI) Total events Heterogeneity: Not application Test for overall effect: $Z = T$ Total events Heterogeneity: Not application Test for overall effect: $Z = T$ Total events Heterogeneity: Not application Total events Heterogeneity: $\chi^2 = 4.67$	Lap Events 0 0 0 1 0 1 0 1 1 0 1 1 0 1 1 2 3 2 3 df = 1 (P 0.28 (P = 3) 3 ble 0.59 (P = 3) 9 df = 6 (P) 9 df = 6 (P) 1 1 1 1 1 1 1 1 1 1 1 1 1	$\begin{array}{c} p \\ Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \\ = 0.36) \\ = 0.78) \\ 67 \\ 67 \\ 0.56) \\ 275 \\ = 0.50) \end{array}$	Open Events 0 2 0 3 7 7 2 0 3 7 7 2 11 1 1 2 0 9 2 11 1 2 0 9 2 11 1 2 0 9 2 1 2 0 3 7 2 2 0 3 2 2 0 3 7 2 2 1 2 1 2 2 1 1 1 2 1 1 1 1 1 1 1 1 1 1 1 1 1	Total 33 24 268 20 39 384 % 79 38 117 137 137 638	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7% 100.0%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2013 2017	Risk ratio M-H, fixed, 95% CI
Study or subgroupRHBaker et al., 2009Makki et al., 2014Sub, 2014Shen et al., 2016Kitajima et al., -R 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 3.78$, orTest for overall effect: $Z = LH$ Marubashi et al., 2013Kitajima et al., -L 2017Subtotal (95% CI)Total eventsHeterogeneity: $\chi^2 = 0.83$, orTest for overall effect: $Z = RH + LH$ Soyama et al., 2015Subtotal (95% CI)Total eventsHeterogeneity: Not applicatTest for overall effect: $Z = Total (95\% CI)$ Total eventsHeterogeneity: Not applicatTest for overall effect: $Z = Total (95\% CI)$ Total eventsHeterogeneity: $\chi^2 = 4.67$, orTest for overall effect: $\chi^2 = 4.67$, $\chi^2 = 4.$	Lap Events 0 0 0 1 0 1 0 1 1 0 1 1 2 3 4f = 3 (P = 2 3 5 4f = 1 (P 0.28 (P = 3 ble 0.59 (P = 9 4f = 6 (P 1.18 (P))	$\begin{array}{r} p \\ Total \\ 33 \\ 26 \\ 14 \\ 28 \\ 41 \\ 142 \\ = 0.29) \\ = 0.22) \\ 31 \\ 35 \\ 66 \\ = 0.36) \\ = 0.78) \\ 67 \\ 67 \\ 0.56) \\ 275 \\ = 0.59) \\ = 0.59) \\ \end{array}$	Open Events 0 2 2 0 3 ; $I^2 = 215$ 9 2 11 ; $I^2 = 0\%$ 9 9 9 2 2 ; $I^2 = 0\%$	Total 33 24 268 20 39 384 % 79 38 117 137 137 638	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7% 100.0%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2013 2017 2015	Risk ratio M-H, fixed, 95% CI
Study or subgroup RH Baker et al., 2009 Makki et al., 2014 Sub, 2014 Shen et al., 2016 Kitajima et al., -R 2017 Subtotal (95% CI) Total events Heterogeneity: $\chi^2 = 3.78$, of Test for overall effect: $Z = LH$ Marubashi et al., 2013 Kitajima et al., -L 2017 Subtotal (95% CI) Total events Heterogeneity: $\chi^2 = 0.83$, of Test for overall effect: $Z = RH + LH$ Soyama et al., 2015 Subtotal (95% CI) Total events Heterogeneity: Not applicat Test for overall effect: $Z = T$ Total (95% CI) Total events Heterogeneity: Not applicat Test for overall effect: $Z = T$ Total (95% CI) Total events Heterogeneity: $\chi^2 = 4.67$, of Test for overall effect: $Z = T$ Total coverall effect: $Z = T$	Lap Events 0 0 0 1 0 1 1 0 1 1 2 3 4f = 3 (P = 2 3 5 4f = 1 (P 0.28 (P = 3 ble 0.59 (P = 9 4f = 6 (P 1.18 (P =	$\begin{array}{r} p\\ Total\\ 33\\ 26\\ 14\\ 28\\ 41\\ 142\\ = 0.29)\\ = 0.22)\\ 31\\ 35\\ 66\\ = 0.36)\\ = 0.78)\\ 67\\ 67\\ 0.56)\\ 275\\ = 0.59)\\ = 0.24)\\ 0.56)\\ 275\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.24)\\ 0.56\\ = 0.24)\\ 0.56\\ = 0.24)\\ 0.56\\ = 0.24)\\ 0.56\\ = 0.59)\\ = 0.24)\\ 0.56\\ = 0.240\\ =$	Open Events 0 2 0 2 0 3 7 9 2 11 ; $I^2 = 0\%$ 9 9 <tr< td=""><td>Total 33 24 268 20 39 384 % 79 38 117 137 137 638</td><td>Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7% 100.0%</td><td>Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]</td><td>Year 2009 2014 2016 2017 2013 2013 2017 2015 </td><td>Risk ratio M-H, fixed, 95% CI</td></tr<>	Total 33 24 268 20 39 384 % 79 38 117 137 137 638	Weight 13.0% 1.3% 2.9% 18.0% 35.3% 25.5% 9.6% 35.1% 29.7% 29.7% 100.0%	Risk ratio M-H, fixed, 95% CI Not estimable 0.19 [0.01, 3.67] 3.59 [0.18, 71.43] 2.17 [0.09, 50.74] 0.14 [0.01, 2.55] 0.45 [0.13, 1.60] 0.57 [0.13, 2.47] 1.63 [0.29, 9.18] 0.86 [0.29, 2.55] 0.68 [0.19, 2.44] 0.68 [0.19, 2.44]	Year 2009 2014 2016 2017 2013 2013 2017 2015 	Risk ratio M-H, fixed, 95% CI

FIGURE 3: Forest plot of subgroup analyses. (a) Overall postoperative complications. (b) Clavien grade I complication. (c) Clavien grade II complication. (d) Clavien grade III complication. Lap: laparoscopy-assisted living donor hepatectomy, Open: open donor hepatectomy, RH: right lobe hepatectomy, LH: left lobe hepatectomy, and RH + LH: mixed group.

(d)

Study or subgroup		Lap			Open		Weight	Mean difference	Voor	Mean difference
Study of Subgroup	Mean	SD	Total	Mean	SD	Total	weight	IV, fixed, 95% CI	Ical	IV, fixed, 95% CI
Thenappan et al., 2011	47.6	23.2	15	56.8	40.2	15	8.7%	-0.27 [-0.99, 0.45]	2011	
Choi et al., 2012	2.5	1.1	20	2.55	1.1	90	19.2%	-0.05 [-0.53, 0.44]	2012	
Makki et al., 2014	140.76	27.92	26	172.71	52.24	24	13.6%	-0.76 [-1.34, -0.18]	2014	
Shen et al., 2016	2.8	0.9	28	3	0.7	20	13.6%	-0.24 [-0.81, 0.34]	2016	
Kitajima et al., 2017	255	227.5	76	279	161.7	77	44.9%	-0.12 [-0.44, 0.20]	2017	
Total (95% CI)			165			226	100.0%	-0.22 [-0.44, -0.01]		•
Heterogeneity: $\chi^2 = 4.2$	27, df = 4	4(P = 0	.37); I ²	= 6%					-	
Test for overall effect: Z	2 = 2.05	(P = 0.0))4)							-1 -0.5 0 0.5 1
										Favours [lap] Favours [open]

FIGURE 4. Forest	plot of	meta an	alveeeana	loesic use
I IGURE 4. I DICSU	101 01	incla and	aryses—ana	igeoie use.

Study or subgroup		Lap			Open		Weight	Mean difference	Vear	Mean diffe	rence	
Study of subgroup	Mean	SD	Total	Mean	SD	Total	weight	IV, random, 95% CI	Ical	IV, random,	95% CI	
RH												
Baker et al., 2009	265	48	33	316	61	33	10.2%	-51.00 [-77.48, -24.52]	2009			
Choi et al., 2012	383.55	41.73	20	303.22	61.49	90	10.5%	80.33 [58.06, 102.60]	2012			\rightarrow
Makki et al., 2014	702.5	124.1	26	675.2	117.5	24	6.8%	27.30 [-39.67, 94.27]	2014			
Sub, 2014	338.8	61.7	14	275.9	45.7	268	9.7%	62.90 [30.12, 95.68]	2014			
Soyama et al.,-R 2015	431.75	74.2	25	425.75	49.95	25	9.5%	6.00 [-29.06, 41.06]	2015			
Shen et al., 2016	386.1	49.5	28	366.4	45.3	20	10.1%	19.70 [-7.32, 46.72]	2016			
Kitajima et al.,-R 2017	432	74	41	410	68	39	9.8%	22.00 [-9.12, 53.12]	2017			
Subtotal (95% CI)			187			499	66.7%	23.86 [-13.72, 61.44]				
Heterogeneity: $\tau^2 = 2248$	8.10; χ^2	= 61.72,	df = 6 (1	P < 0.000	01); I ² =	= 90%						
Test for overall effect: Z	= 1.24 (1	P = 0.21)									
LH												
Marubashi et al., 2013	435	103	31	383	73	79	9.1%	52.00 [12.33, 91.67]	2013			
Soyama et al.,-L 2015	438.25	111.2	41	478	142.1	39	7.7%	-39.75 [-95.85, 16.35]	2015 —		_	
Kitajima et al.,-L 2017	444	79	35	406	80	38	9.4%	38.00 [1.50, 74.50]	2017			
Subtotal (95% CI)			107			156	26.3%	20.92 [-26.85, 68.69]				
Heterogeneity: $\tau^2 = 1279$	9.48; χ^2	= 7.29, 0	df = 2 (P	= 0.03); 1	$I^2 = 739$	6						
Test for overall effect: \boldsymbol{Z}	= 0.86 (1	P = 0.39)									
RH + LH												
Thenannan et al. 2011	435	103	15	383	73	15	71%	52 00 [-11 89 115 89]	2011			\rightarrow
Subtotal (95% CI)	100	105	15	505	75	15	7.1%	52.00 [-11.89, 115.89]	2011			
Heterogeneity. Not appli	cable											
Test for overall effect: Z	= 1.60 (F	P = 0.11										
	(-	,										
Total (95% CI)			309			670	100.0%	24.85 [-3.09, 52.78]				
Heterogeneity: $\tau^2 = 1813$	3.35; χ^2	= 69.61,	df = 10	(P < 0.000)	001); I ²	= 86%			· · · ·		i	
Test for overall effect: Z	= 1.74 (1	P = 0.08)						-100	-50 0	50	100
Test for subgroup differe	nces: χ^2	= 0.67,	df = 2 (P	= 0.71),	$I^2 = 0\%$					Favours [lap]	Favours [open]	

FIGURE 5: Forest plot of subgroup analyses—operation time. Lap: laparoscopy-assisted living donor hepatectomy, Open: open donor hepatectomy, RH: right lobe hepatectomy, LH: left lobe hepatectomy, and RH + LH: mixed group.

symmetrically. This result suggested that the publication bias was acceptable (Figure 9).

4. Discussion

Minimally invasive donor surgery was developed to reduce the morbidity and decrease the impact on the donor, minimizing tissue trauma, and improving postoperative pain and cosmesis for patients. LADH with manual hand manipulation in the abdominal cavity, giving the surgeon enhanced tactile feedback of the liver, allowed for more precise mobilization and dissection of the targeted lobe. This technique is combined with smaller incision while preserving the maneuverability and safety of an open liver resection. LADH apparently leads to less wound-related morbidity and the best cosmetic result [16]. In a recent review, Xu et al. [17] examined laparoscopic versus open liver resection for liver transplantation, showing less blood loss, shortened hospital stay, and longer operation time. However, this review did not attempt to clarify the different types of laparoscopic

Study or subgroup	L	ap	Op	en	Weight	Risk ratio	Vear	Risk	k ratio	
Study of subgroup	Events	Total	Events	Total	weight	M-H, fixed, 95% CI	Ical	M-H, fix	ed, 95% CI	
Thenappan et al., 2011	0	15	0	15		Not estimable	2011			
Makki et al., 2014	1	26	3	24	65.2%	0.31 [0.03, 2.76]	2014		<u> </u>	
Shen et al., 2016	2	28	1	20	24.4%	1.43 [0.14, 14.70]	2016			
Kitajima et al., 2017	1	76	0	77	10.4%	3.04 [0.13, 73.45]	2017		•	
Total (95% CI)		145		136	100.0%	0.86 [0.24, 3.12]				
Total events	4		4							
Heterogeneity: $\chi^2 = 1.6$	3, df = 2 (.	P = 0.44); $I^2 = 0\%$	6				1		
Test for overall effect: Z	= 0.22 (P	r = 0.82					0.0	1 0.1	1 10	100
	(-	,						Favours [LA]	Favours [open]	

FIGURE 6: Forest plot of meta analyses—transfusion. Lap: laparoscopy-assisted living donor hepatectomy, Open: open donor hepatectomy.

Study or subgroup		Lap			Open		Waight	Mean difference	Voor	Mean difference
study of subgroup	Mean	SD	Total	Mean	SD	Total	weight	IV, random, 95% CI	Ieal	IV, random, 95% CI
RH										
Baker et al., 2009	4.3	4.4	33	3.9	16.7	33	4.0%	0.40 [-5.49, 6.29]	2009	
Choi et al., 2012	12.1	2.81	20	12	3.61	90	18.1%	0.10 [-1.34, 1.54]	2012	-+-
Marubashi et al., 2013	10.3	3.3	31	18.3	16.7	79	7.6%	-8.00 [-11.86, -4.14]	2013	
Sub, 2014	10.2	4.4	14	9.2	3.3	268	13.3%	1.00 [-1.34, 3.34]	2014	- +
Shen et al., 2016	7.4	2.5	28	7.3	1.6	20	19.6%	0.10 [-1.06, 1.26]	2016	- + -
Kitajima et al.,-R 2017 Subtotal (95% CI)	13	4	41 167	14	8	39 529	11.2% 73.8%	-1.00 [-3.79, 1.79] -0.84 [-2.58, 0.91]	2017	
Heterogeneity: $\tau^2 = 2.9$	$00; \chi^2 =$	17.46	df = 5	(P = 0.	004);	$I^2 = 71^{\circ}$	%			
Test for overall effect: Z	Z = 0.94	(<i>P</i> =	0.35)							
LH										
Kitajima et al.,-L 2017 Subtotal (95% CI)	14	7	35 35	13	4	38 38	11.8% 11.8%	1.00 [-1.64, 3.64] 1.00 [-1.64, 3.64]	2017	
Heterogeneity: Not app	licable									
Test for overall effect: Z	2 = 0.74	(<i>P</i> =)	0.46)							
RH + LH										
Thenappan et al., 2011 Subtotal (95% CI)	6	2	15 15	6.4	3.68	15 15	14.4% 14.4%	-0.40 [-2.52, 1.72] -0.40 [-2.52, 1.72]	2011	
Heterogeneity: Not app	licable									
Test for overall effect: Z	2 = 0.37	(P = 0)	.71)							
Total (95% CI)			217			582	100.0%	-0.47 [-1.78, 0.83]		•
Heterogeneity: $\tau^2 = 1.9$	90; $\chi^2 =$	18.27	, df = 7	P = 0	.01); I	² = 62%	6			
Test for overall effect: Z	Z = 0.72	(P = 0)	0.47)							-10 -5 0 5 10
Test for subgroup differ	ences: y	$\chi^2 = 1$.30, df	= 2 (P =	= 0.52), $I^2 = 0$)%			Favours [LA] Favours [open]

FIGURE 7: Forest plot of subgroup analyses—length of hospital stay. Lap: laparoscopy-assisted living donor hepatectomy, Open: open donor hepatectomy, RH: right lobe hepatectomy, LH: left lobe hepatectomy, and RH + LH: mixed group.

Study or subgroup	Mean	Lap SD	Total	Open Mean SD To		Total	Weight Mean difference IV, fixed, 95% CI		Year		Mean difference IV, fixed, 95% CI			
Baker et al., 2009	900	215	33	914	160	33	11.3%	-14.00 [-105.44, 77.44]	2009			-		_
Makki et al., 2014	755.5	87.94	26	725.8	134.4	24	23.5%	29.70 [-33.81, 93.21]	2014				-	
Shen et al., 2016	634.2	124.2	28	572.9	122.5	20	18.9%	61.30 [-9.40, 132.00]	2016			-	-	
Kitajima et al.,-R 2017	724	184.8	41	710	150.1	39	17.5%	14.00 [-59.61, 87.61]	2017			-		
Kitajima et al.,-L 2017	413	99.6	35	455	147.2	38	28.8%	-42.00 [-99.26, 15.26]	2017		-	+		
Total (95% CI)			163			154	100.0%	7.31 [-23.45, 38.07]			-			
Heterogeneity: $\chi^2 = 5.81$, df = 4 (P = 0.21); $I^2 = 31\%$									-					
Test for overall effect: $Z = 0.47$ ($P = 0.64$)									-100	-50	0	50	100	
· · ·									Favours [open] Favours [LA]					

FIGURE 8: Forest plot of meta analyses—graft weight.



FIGURE 9: Funnel plot of overall postoperative complications. RH: right lobe hepatectomy, LH: left lobe hepatectomy, and RH + LH: mixed group.

surgery. In our meta-analysis, we only included the studies of laparoscopy-assisted (hybrid) surgery. Our further subgroup analysis was done to learn how LADH affects surgery in different areas of the liver.

Our result confirms that blood loss was significantly less in the LADH group than in the ODH group. This is consistent with published results for laparoscopic hepatectomies, even when laparoscopy is only used for the hepatic mobilization [18]. In the subgroup analysis of single types of hepatectomy to minimize the bias, there was no difference between the types of donor hepatectomy. LADH is a potential technique to decrease blood loss, confirmed by the colorectal surgery [19] and prior analysis [20]. Hand-assisted surgery has been promoted by its advocates in decreased complication rate in the colorectal surgery [19]. Our analysis of LADH demonstrated favourable overall complication rates compared to ODH, similar to the previous analysis [20]. In the subgroup analysis, LH shows a significantly lower rate of complications in the LADH group, which accounts for the lower complication rate in the total group. However, the case volume is small in the left hepatectomy subgroup. In theory, it is easier to mobilize the right lobe from the diaphragm by laparoscopic technique and inferior vena cava with the help of manual manipulation. Adequate mobilization, improved visualization, and better manipulation contribute to the enhanced safety of the operation. Living donor mortality in ODH was reported as 0.2% (23/1153), mostly related to surgical procedure [21]. There was no mortality to be reported in the studies both in laparoscopy-assisted and open group for donor. In other words, LADH shows a better tendency toward in the outcome of morbidity to ODH.

Smaller and midline incisions in the supraumbilical area resulted in reduced disruption of abdominal muscles, deceased scar discomfort, and less postoperative analgesic use in our analysis, raising the possibility of better cosmetic results and, possibly, faster return to work and normal physical activities. However, it tended to have an increased operative time associated with hand-assisted surgery, though it did not reach statistical significance. The result could be explained by the application of laparoscopic instruments for the meticulous mobilization in the liver surgery. Furthermore, the transfusion rate was comparable between LADH and ODH in this analysis. Additionally, LOS demonstrated no inferiority for LADH. Interestingly, the prior meta-analysis of laparoscopic versus open hepatectomy for live liver donor has shown the significantly shorter hospital stay in the LADH group [17, 20]. This may be ascribed to the methods of surgery and postoperation protocols and insurance policy. Regarding hospital cost, it was higher in the LADH. From published data, the overall cost of laparoscopic liver resection was lower than open liver resection [22].

After comparing laparoscopic-assisted operation and open operation, there was a high heterogeneity in the analysis, even in the subgroup analyses by type of surgery. These may result from differences in study designs, number of participants, donors' baseline characteristics, surgical techniques, and surgical types. In addition, some of the data estimated the mean and SD from median and range, which may result in inaccuracy. No random trials were included and most of the studies were cohort studies or case-control studies. Because of high-risk in the donor hepatectomy, a relative surgical abstention may present in the enrolled patients and their families. Based on these limitations, larger prospective studies and randomized trials are needed.

5. Conclusion

According to our data, laparoscopy-assisted living donor hepatectomy (LADH) is equally safe and effective technique. There was no increased risk of morbidity compared to ODH patients in our examined groups. Benefits of laparoscopy-assisted donor hepatectomy compared to open surgery have demonstrated improved short-term outcomes, especially lower intraoperative blood loss and complications. We conclude that LADH is an appropriate minimally invasive procedure for living donor hepatectomies, which needs to be selected by patients' and surgery' preferences.

Abbreviations

- LADH: Laparoscopy-assisted living donor hepatectomy
- ODH: Open donor hepatectomy
- LLR: Laparoscopic liver resection
- WMD: Weighted mean difference
- SMD: Standard mean difference
- RR: Risk ratio
- SD: Standard deviation
- NOS: Newcastle-Ottawa Quality Assessment Scale
- RH: Right lobe hepatectomy
- LH: Left lobe hepatectomy
- ALT: Alanine aminotransferase
- AST: Aspartate aminotransferase
- TB: Total bilirubin
- LFT: Liver function test.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

Bin Zhang and Yu Pan wrote the paper and performed the research. Xiu-jun Cai and Ke Chen designed the study. Ming-Yu Chen and He-Pan Zhu collected the data. Hendi Maher and Yi-Bin Zhu performed the literature search and retrieved the data. Xiu-jun Cai, Jiang Chen, and Yi Dai analyzed the data and revised the manuscript.

Acknowledgments

This study was supported by Research Project of Zhejiang Provincial Education Department (no. N20140173).

References

- S. Raia, J. R. Nery, and S. Mies, "Liver transplantation from live donors," *The Lancet*, vol. 334, no. 8661, p. 497, 1989.
- [2] D. G. Maluf, R. T. Stravitz, A. H. Cotterell et al., "Adult living donor versus deceased donor liver transplantation: A 6-year single center experience," *American Journal of Transplantation*, vol. 5, no. 1, pp. 149–156, 2005.
- [3] D. Cherqui, O. Soubrane, E. Husson et al., "Laparoscopic living donor hepatectomy for liver transplantation in children," *The Lancet*, vol. 359, no. 9304, pp. 392–396, 2002.
- [4] A. J. Koffron, R. Kung, T. Baker, J. Fryer, L. Clark, and M. Abecassis, "Laparoscopic-assisted right lobe donor hepatectomy," *American Journal of Transplantation*, vol. 6, no. 10, pp. 2522–2525, 2006.
- [5] T. Kitajima, T. Kaido, T. Iida et al., "Short-term outcomes of laparoscopy-assisted hybrid living donor hepatectomy: a comparison with the conventional open procedure," *Surgical Endoscopy*, pp. 1–10, 2017.
- [6] S. P. Hozo, B. Djulbegovic, and I. Hozo, "Estimating the mean and variance from the median, range, and the size of a sample," *BMC Medical Research Methodology*, vol. 5, article 13, 2005.
- [7] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses," *British Medical Journal*, vol. 327, no. 7414, pp. 557–560, 2003.
- [8] T. B. Baker, C. L. Jay, D. P. Ladner et al., "Laparoscopy-assisted and open living donor right hepatectomy: A comparative study of outcomes," *Surgery*, vol. 146, no. 4, pp. 817–825, 2009.
- [9] A. Thenappan, R. C. Jha, T. Fishbein et al., "Liver allograft outcomes after laparoscopic-assisted and minimal access live donor hepatectomy for transplantation," *The American Journal* of Surgery, vol. 201, no. 4, pp. 450–455, 2011.
- [10] H. J. Choi, Y. K. You, G. H. Na, T. H. Hong, G. S. Shetty, and D. G. Kim, "Single-port laparoscopy-assisted donor right hepatectomy in living donor liver transplantation: Sensible approach or unnecessary hindrance?" *Transplantation Proceedings*, vol. 44, no. 2, pp. 347–352, 2012.
- [11] S. Marubashi, H. Wada, K. Kawamoto et al., "Laparoscopyassisted hybrid left-side donor hepatectomy," *World Journal of Surgery*, vol. 37, no. 9, pp. 2202–2210, 2013.
- [12] K. Makki, V. K. Chorasiya, G. Sood, P. K. Srivastava, P. Dargan, and V. Vij, "Laparoscopy-assisted hepatectomy versus

conventional (open) hepatectomy for living donors: When you know better, you do better," *Liver Transplantation*, vol. 20, no. 10, pp. 1229–1236, 2014.

- [13] A. Soyama, M. Takatsuki, M. Hidaka et al., "Hybrid procedure in living donor liver transplantation," *Transplantation Proceedings*, vol. 47, no. 3, pp. 679–682, 2015.
- [14] S.-W. Suh, K.-W. Lee, J.-M. Lee, Y. Choi, N.-J. Yi, and K.-S. Suh, "Clinical outcomes of and patient satisfaction with different incision methods for donor hepatectomy in living donor liver," *Liver Transplantation*, vol. 21, no. 1, pp. 72–78, 2015.
- [15] S. Shen, W. Zhang, L. Jiang, L. Yan, and J. Yang, "Comparison of Upper Midline Incision With and Without Laparoscopic Assistance for Living-Donor Right Hepatectomy," *Transplantation Proceedings*, vol. 48, no. 8, pp. 2726–2731, 2016.
- [16] A. Jain, P. Nemitz, R. Sharma et al., "Incidence of abdominal wall numbness post-liver transplantation and its complications," *Liver Transplantation*, vol. 15, no. 11, pp. 1488–1492, 2009.
- [17] J. Xu, C. Hu, H.-L. Cao et al., "Meta-analysis of laparoscopic versus open hepatectomy for live liver donors," *PLoS ONE*, vol. 11, no. 10, Article ID e0165319, 2016.
- [18] H.-S. Han, A. Shehta, S. Ahn, Y.-S. Yoon, J. Y. Cho, and Y. Choi, "Laparoscopic versus open liver resection for hepatocellular carcinoma: Case-matched study with propensity score matching," *Journal of Hepatology*, vol. 63, no. 3, article no. 5641, pp. 643–650, 2015.
- [19] H. Moloo, F. Haggar, D. Coyle et al., "Hand assisted laparoscopic surgery versus conventional laparoscopy for colorectal surgery," *Cochrane Database of Systematic Reviews*, no. 10, Article ID CD006585, 2010.
- [20] G. Berardi, F. Tomassini, and R. I. Troisi, "Comparison between minimally invasive and open living donor hepatectomy: A systematic review and meta-analysis," *Liver Transplantation*, vol. 21, no. 6, pp. 738–752, 2015.
- [21] Y. L. Cheah, M. A. Simpson, J. J. Pomposelli, and E. A. Pomfret, "Incidence of death and potentially life-threatening near-miss events in living donor hepatic lobectomy: a world-wide survey," *Liver Transplantation*, vol. 19, no. 5, pp. 499–506, 2013.
- [22] S. P. Cleary, H.-S. Han, M. Yamamoto, G. Wakabayashi, and H. J. Asbun, "The comparative costs of laparoscopic and open liver resection: a report for the 2nd International Consensus Conference on Laparoscopic Liver Resection," *Surgical Endoscopy*, vol. 30, no. 11, pp. 4691–4696, 2016.